Micro-X Lands Record $3.3M Rover Plus Order, Advances Head CT Trials

Commercial Breakthroughs

Micro-X Ltd (ASX, MX1), a pioneer in cold cathode x-ray technology, has reported a landmark quarter with its largest single order ever, a $3.3 million purchase of Rover Plus mobile x-ray units by the Malaysian Ministry of Health. This order, secured through local distributor Integrated Medical Systems, underscores Micro-X’s growing footprint in Southeast Asia and validates the Rover Plus as a versatile, reliable imaging solution for healthcare providers.

Alongside this, Micro-X is actively engaging a major US healthcare customer operating over 700 facilities, following a supply agreement signed in July 2025. This relationship offers a streamlined sales channel without the need for tender processes, potentially accelerating adoption across a vast network.

Operational Milestones in Medical Imaging

On the innovation front, Micro-X has completed the first test bench for its Head CT scanner, designed to enable rapid stroke diagnosis directly in ambulances. Pending ethics and regulatory approvals, hospital imaging trials in Australia are set to commence, marking a significant step toward regulatory submissions planned for 2026.

Supporting this development, the company secured a $4.4 million Industry Growth Program grant to fund world-first ambulance trials in partnership with the South Australian Ambulance Service and Royal Adelaide Hospital. The grant’s initial $1.1 million tranche was received in October, enabling prototype development and integration into active ambulances.

Expanding Security and Product Development

Micro-X’s security division also advanced, with a contract extension from the US Department of Homeland Security worth up to $2.5 million, bringing total DHS contracted value to approximately US$20.9 million. The company showcased its baggage scanner prototype publicly for the first time and delivered a prototype baggage and parcel scanner to partner Billion Prima, aiming for a commercial launch in 2026.

Financial Position and Outlook

Financially, Micro-X ended the quarter with $2.0 million in cash, or $2.8 million pro forma after accounting for the FY2025 R&D tax rebate and loan repayment. The company reported net cash outflows of $1.2 million for the quarter but holds $17.8 million in contracted consulting receipts for FY2026, subject to milestone achievements. CEO Kingsley Hall highlighted the company’s strategic focus on scaling Rover Plus sales, advancing Head CT trials, and monetising security assets through partnerships.

Looking ahead, Micro-X is poised to deliver the balance of the Malaysian order by mid-November and expects further revenue from ongoing US healthcare engagements and government grants. The upcoming clinical trial results and regulatory progress will be critical to watch as the company moves closer to commercialising its innovative medical imaging technologies.